

AMENDMENTS TO THE CLAIMS

Claim 1 (Previously presented): A method of screening or validating an antiestrogen, said method comprising screening a test compound for the ability to activate transcription through an indirect estrogen response, the method comprising:

- a) providing a cell comprising AP1 proteins, an estrogen receptor and a promoter comprising an AP1 site which regulates expression of a reporter gene;
- b) contacting the cell with the test compound; and
- c) detecting the expression of the reporter gene, wherein enhanced expression of the reporter gene indicates that said test compound has the ability to activate transcription through an indirect estrogen response and is not fully antiestrogenic.

Claim 2 (Previously presented): The method of claim 1, wherein the cell is an Ishikawa cell.

Claim 3 (Previously presented): The method of claim 1, wherein the cell over-expresses the estrogen receptor.

Claim 4 (Previously presented): The method of claim 1, wherein the promoter is genetically engineered to comprise an AP1 site.

Claim 5 (Previously presented): The method of claim 1, wherein the test compound is known to have antiestrogenic activity.

Claim 6 (Previously presented): The method of claim 1, wherein the cell is derived from uterine tissue.

Claim 7 (Previously presented): The method of claim 6, wherein the cell is a HeLa cell or an Ishikawa cell.

Claim 8 (Previously presented): A method of claim 1, further comprising the steps of:

- a) providing a second cell comprising an estrogen receptor and a promoter comprising a standard estrogen response element which regulates expression of a second reporter gene;
- b) contacting the second cell with the test compound; and

c) detecting the expression of the second reporter gene.

Claim 9 (Previously presented): A method of claim 8, wherein the response element is from the *Xenopus vitellogenin A2* gene.

Claim 10 (Previously presented): A method of claim 1, wherein the cell further comprises a promoter comprising a standard estrogen response element which regulates expression of a second reporter gene.

Claim 11 (Previously presented): A method of claim 10, wherein the response element is from the *Xenopus vitellogenin A2* gene.

Claim 12 (Canceled).

¹²
Claim ~~13~~ (Previously presented): A method of screening or validating an antiestrogen, said method comprising screening a test compound for the ability to inhibit transcription through an indirect estrogen response, the method comprising:

a) providing a cell comprising AP1 proteins, an estrogen receptor and a promoter comprising an AP1 site which regulates expression of a reporter gene;

b) contacting the cell with the test compound and a compound known to mediate an indirect estrogen response;

c) detecting the expression of the reporter gene, wherein inhibition of expression of said reporter gene produced by said compound known to mediate an indirect estrogen response indicates that said test compound inhibits transcription through an indirect estrogen response and is a candidate antiestrogen.

¹³
Claim ~~14~~ (Previously presented): The method of claim ¹²~~13~~, wherein the compound [is] known to mediate an indirect estrogen response is tamoxifen.

¹⁴
Claim ~~15~~ (Previously presented): A method of claim ¹²~~13~~, wherein the cell over-expresses the estrogen receptor.

Claim ~~16~~¹⁵ (Previously presented): The method of claim ~~13~~¹³, wherein the promoter is genetically engineered to comprise an AP1 site.

Claim 17 (Canceled).

Claim ~~18~~¹⁶ (Previously presented): A method for screening a test environmental compound for estrogenic activity mediated through an indirect estrogen response, the method comprising:

- a) providing a cell comprising AP1 proteins, an estrogen receptor and a promoter comprising an AP1 site which regulates the expression of a reporter gene;
- b) contacting the cell with the test compound; and
- c) detecting the expression of the reporter gene, wherein enhanced expression of the reporter gene indicates that said environmental compound has estrogenic activity.

Claim ~~19~~¹⁷ (Previously presented): The method of claim ~~18~~¹⁶, wherein the cell further comprises a promoter comprising an estrogen response element (ERE) which regulates expression of a second reporter gene.

Claim ~~20~~¹⁸ (Previously presented): The method of claim ~~18~~¹⁶, where the reporter gene is CVAT.

Claim ~~21~~¹⁹ (Previously presented): The method of claim ~~18~~¹⁶, wherein the cell over-expresses the estrogen receptor.

Claim ~~22~~²⁰ (Previously presented): The method of claim ~~18~~¹⁶, wherein the cell is an ERC1 cell.

Claims 23-29 (Canceled).